Clinical Trial Update: Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 safety study of elotuzumab in combination with thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma has completed, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Empliciti (elotuzumab)
• Thalomid (thalidomide)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Relapsed and/or Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2016-02-26